Russell Fryer, CEO of Critical Metals, discusses bringing Molulu back into production. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Share News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.615
Bid: 1.58
Ask: 1.65
Change: 0.002 (0.12%)
Spread: 0.07 (4.43%)
Open: 1.613
High: 0.00
Low: 0.00
Prev. Close: 1.613
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

29 Feb 2024 14:04

Hemogenyx Pharmaceuticals raises money for leukaemia treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it has raised GBP3.3 million through a placing.

Read more
16 Feb 2024 11:27

Hemogenyx shares rise on potential for CBR to treat brain diseases

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said research has shown that its proprietary chimeric bait receptor can be delivered into the brain through programmed microglial cells and could be used for the treatment of brain cancers and some neurodegenerative diseases.

Read more
14 Feb 2024 10:14

Hemogenyx says CBR can be used intranasally to treat viral infections

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said its chimeric bait receptor can be delivered intranasally in the form of messenger RNA for the "potential" treatment of airborne viral infections.

Read more
9 Feb 2024 10:00

IN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - US Food & Drug Administration has lifted clinical hold on company's investigational new drug application for Hemo-Car-T to treat acute myeloid leukemia. FDA placed therapy on clinical hold in July due to a splicing deficiency during manufacture of the lentivirus used to produce Car-T cells. Hemogenyx in August produced a "detailed plan, supported by laboratory tests" to address FDA's concerns, which was accepted the following month.

Read more
2 Feb 2024 10:44

IN BRIEF: Hemogenyx hails US patent application progress

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - Celebrates as patent application is allowed by the US Patent & Trademark Office. The patent is for the process of eliminating hematopoietic stem cells or hematopoietic progenitors in a patient using bi-specific antibodies.

Read more
16 Jan 2024 11:13

Hemogenyx Pharmaceuticals sends complete response on HEMO-CAR-T to FDA

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Tuesday said it submitted a complete response to the previously announced clinical hold of the investigational new drug application to the US Food & Drug Administration.

Read more
8 Jan 2024 10:56

Hemogenyx Pharmaceuticals completes process qualification run

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said it completed a process qualification run.

Read more
28 Nov 2023 16:53

TRADING UPDATES: Upland Resources completes technical study at Sarawak

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
27 Nov 2023 10:52

Hemogenyx shares up as says CBR platform a potential cancer treatment

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday said its chimeric based receptor platform could "potentially" be used to treat cancer and viral diseases.

Read more
15 Nov 2023 15:43

Hemogenyx Pharmaceuticals completes lentivirus re-manufacture

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said it has completed the re-manufacturing of an improved lentivirus devoid of splice variants.

Read more
28 Sep 2023 14:24

EARNINGS: Dar Global profit multiplies, Hemogenyx loss widens

(Alliance News) - The following is a round-up of earnings updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Sep 2023 14:37

TRADING UPDATES: Avingtrans buys Adaptix, TPXimpact sells Questers

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
18 Sep 2023 13:00

Hermogenyx shares soar on new partnership with Prevail Partners

(Sharecast News) - Shares in biopharma group Hemogenyx surged on Monday after the company received a $0.83m investment from Prevail Partners as it continues to work on its planned clinical trial for leukaemia treatment.

Read more
14 Sep 2023 14:31

Hemogenyx Pharma says US FDA accepts Hemo-Car-T clinical hold lift plan

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said the US Food & Drug Administration has accepted its plan to address concerns which sparked a clinical hold on its chimeric antigen receptor T-cell or Hemo-Car-T therapy.

Read more
8 Sep 2023 19:43

IN BRIEF: Hemogenyx Pharmaceuticals says patent number published

Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical group developing new therapies and treatments for blood diseases - Says its patent application number "WO2023168292 Chimeric Bait Receptors and Uses Thereof" was published by the World Intellectual Property Organization on Thursday. Says it remains to be reviewed and approved by national patent authorities.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.